Vistagen Therapeutics Faces Class Action Lawsuit Following 80% Stock Plunge

Vistagen Therapeutics (VTGN) is facing a class action lawsuit after its stock price plummeted by more than 80% following the disclosure of clinical trial results. The legal action, filed by Levi & Korsinsky, LLP, aims to recover damages for investors who purchased the company's securities between April 1, 2024, and December 16, 2025. The massive sell-off was triggered by data from clinical trials, which raised significant concerns regarding the company's clinical pipeline and future prospects. Allegations in the lawsuit suggest potential violations of securities laws that may have adversely impacted shareholder value during the specified period. A deadline of March 16, 2026, has been established for investors to move the court to serve as lead plaintiff in the case. This litigation adds significant pressure to the biotech firm as it navigates the fallout from its clinical setbacks and intense market volatility.